Department of General Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China; Tianjin General Surgery Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
Transpl Immunol. 2013 Dec;29(1-4):99-104. doi: 10.1016/j.trim.2013.10.001. Epub 2013 Oct 6.
Regulatory T (Treg) cells play a pivotal role in the maintenance of transplantation tolerance. It is of great interest to induce allograft tolerance mediated by regulatory CD4(+)CD25(+) T cells.
Here we investigated the effect of hydrodynamic IL-35-expressing plasmid injection in combination with a methyltransferase inhibitor (decitabine) on immune function and transplantation tolerance in mice.
We showed that IL-35 and decitabine stimulated the proliferation of CD4(+)CD25(+) Tregs and suppressed CD8(+) T cell proliferation in an allogenic mixed lymphocyte culture in vitro. IL-35 gene therapy and decitabine administration prolonged the survival of the transplanted heart in the heterotopic abdominal heart transplantation model in mice.
The possible mechanism through which IL-35 and decitabine treatment increased the survival of graft tissues is to enhance the proliferation of CD4(+)CD25(+) Treg cells and suppress the generation and function of effector T cells. Thus, IL-35 gene therapy combined with decitabine provides a novel approach to induce transplantation tolerance.
调节性 T(Treg)细胞在维持移植耐受中发挥着关键作用。诱导由调节性 CD4+CD25+T 细胞介导的同种异体移植物耐受具有重要意义。
在这里,我们研究了水动力 IL-35 表达质粒注射联合甲基转移酶抑制剂(地西他滨)对小鼠免疫功能和移植耐受的影响。
我们表明,IL-35 和地西他滨刺激 CD4+CD25+Treg 的增殖,并在体外同种混合淋巴细胞培养中抑制 CD8+T 细胞的增殖。IL-35 基因治疗和地西他滨给药延长了小鼠异位腹内心脏移植模型中移植心脏的存活时间。
IL-35 和地西他滨治疗增加移植物组织存活的可能机制是增强 CD4+CD25+Treg 细胞的增殖并抑制效应 T 细胞的生成和功能。因此,IL-35 基因治疗联合地西他滨为诱导移植耐受提供了一种新方法。